Oct 28, 2021
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Oct 27, 2021
Immutep Quarterly Activities Report
Sep 30, 2021
Immutep to present Phase II TACTI-002 data at SITC 2021
Sep 28, 2021
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
Immutep to Present at Healthcare Investor Conferences
Sep 20, 2021
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Sep 01, 2021
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Aug 30, 2021
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Aug 26, 2021
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Aug 04, 2021
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Jul 13, 2021
Jul 05, 2021
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
